News | April 24, 2008

Everolimus DES Improves Outcomes for CAD Patients

April 25, 2008 - An everolimus-eluting stent compared with a paclitaxel-eluting stent resulted in reduced angiographic late loss, noninferior rates of target vessel failure, and fewer major adverse cardiac events during one-year of follow-up in a recent study published in JAMA.

Gregg W. Stone, M.D. (Columbia University Medical Center and the Cardiovascular Research Foundation, New York) and colleagues aimed to evaluate the safety and efficacy of an everolimus-eluting stent compared with a widely used paclitaxel-eluting stent.

To compare everolimus-releasing stents with paclitaxel-releasing stent, Stone and colleagues conducted the SPIRIT III trial using a sample of 1,002 patients with coronary artery disease. During randomization, 669 patients received the everolimus-releasing stent and 333 received the paclitaxel-releasing stent. After 8 months, 436 of 564 patients who were scheduled for an angiographic follow-up completed it, and clinical follow-ups occurred after 1, 6, 9, and 12 months.

Results showed that restenosis as measured by angiography was significantly lowered in the group receiving the everolimus-releasing stent compared to the paclitaxel group. After 9 months, 7.2 percent of patients receiving everolimus stents compared to 9.0 percent receiving paclitaxel stents demonstrated target vessel failure. The risk of major adverse cardiac events (cardiac death, heart attack, or target vessel revascularization) at nine months was reduced by 44 percent in patients receiving the everolimus stent compared with the paclitaxel stent. After one year, this reduction in risk was 42 percent, and it can be explained by fewer heart attacks and target lesion revascularization procedures for patients receiving everolimus.

"This large-scale, prospective, randomized, single-blind, controlled study demonstrates that an everolimus-eluting stent compared with a widely used paclitaxel-eluting stent results in a significant reduction in angiographic in-segment late loss at eight months, with noninferior nine-month rates of ischemia-driven target vessel failure," said the researchers.

Manesh R. Patel, M.D. (Duke University, Durham, N.C.) and David R. Holmes, Jr., M.D. (Mayo Clinic, Rochester, Minn.), in an accompanying editorial, believe that the results found by Stone and colleagues are optimistic.

"These data are encouraging and would qualify as demonstrating biological plausibility and mechanistic effect at the level of a phase 2 study," they said. "What happens next with the everolimus-eluting stent is critical. The current data from the SPIRIT III trial are analogous to the initial comparisons of drug-eluting versus bare-metal stents. Restenosis is reduced with the everolimus stent, potentially with a clinical reduction in target lesion revascularization and myocardial infarction [heart attack]. The clinical effect in a broad population of patients who may be clinically exposed following device approval is unknown. Furthermore, clinical efficacy without any mandated angiographic analysis and long-term safety remain important unanswered clinical issues. Postmarketing approval registries, although complex and expensive to perform optimally, may not address both these concerns."

Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease: A Randomized Trial
Gregg W. Stone; Mark Midei; William Newman; Mark Sanz; James B. Hermiller; Jerome Williams; Naim Farhat; Kenneth W. Mahaffey; Donald E. Cutlip; Peter J. Fitzgerald; Poornima Sood; Xiaolu Su; Alexandra J. Lansky; for the SPIRIT III Investigators
JAMA (2008). 299[16]: 1903-1913.

For more information:

Related Content

Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents| January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Overlay Init